Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

101.53
-0.7400-0.72%
Post-market: 101.530.00000.00%19:30 EDT
Volume:74.09K
Turnover:7.53M
Market Cap:1.66B
PE:9.46
High:102.23
Open:102.02
Low:101.24
Close:102.27
52wk High:108.66
52wk Low:69.02
Shares:16.35M
Float Shares:16.35M
Volume Ratio:0.45
T/O Rate:0.45%
Dividend:1.43
Dividend Rate:1.41%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

DBS Keeps Their Buy Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 12

Tylenol Maker, Pharmacy Chains Urge US Appeals Court to Revisit Decision over Alleged Autism Link

Reuters
·
Sep 12

Eli Lilly Stock (LLY) in Focus as Company Completes $3.8 Billion AtaiBeckley Purchase

TIPRANKS
·
Sep 11

Eli Lilly Completes Acquisition of AtaiBeckley

Reuters
·
Sep 11

Lilly Completes Acquisition of Ataibeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions

THOMSON REUTERS
·
Sep 11

Berenberg Lifts Price Target on Merck to $137 From $127, Keeps Hold Rating

MT Newswires Live
·
Sep 11

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
Sep 11

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
Sep 11

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

Top Bristol-Myers Squibb Executive Makes Major Move With Insider Stock Sale

TIPRANKS
·
Sep 11

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 11

Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi Disposes of 6,249 Common Shares Worth $403,700.93

Reuters
·
Sep 11

Champions Oncology Q1 Revenue Rises on Research Services Business

Reuters
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Dow Jones
·
Sep 11

Cheap Biologic Drug Alternatives Stall, Threatening U.S. Healthcare Savings

Dow Jones
·
Sep 11

BMY Targets Pediatric MS Edge With New Ozanimod Study Against Fingolimod

TIPRANKS
·
Sep 11

Bristol-Myers Squibb’s Long-Term Psoriasis Study Brings Fresh Data for BMY Investors

TIPRANKS
·
Sep 11

Bladder Cancer Trial Completion Puts Opdivo in Focus for BMY and Ono Investors

TIPRANKS
·
Sep 11

Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says

MT Newswires Live
·
Sep 11